scholarly journals NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY

2018 ◽  
Vol 20 (suppl_2) ◽  
pp. i142-i142
Author(s):  
Chie-Schin Shih ◽  
Jaishri Blakely ◽  
Wade Clapp ◽  
Pam Wolters ◽  
Eva Dombi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Prospective Study ◽  
Phase Ii ◽  
Neurofibromatosis Type 1 ◽  
Neurofibromatosis Type ◽  
Plexiform Neurofibromas

Phase II trial of the MEK1/2 inhibitor selumetinib (AZD6244) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS2596-TPS2596 ◽  
Author(s):  
Diana Bradford ◽  
Patricia Whitcomb ◽  
Eva Dombi ◽  
Alice P. Chen ◽  
Andrea Baldwin ◽  
...  
Keyword(s):  
Phase Ii ◽  
Neurofibromatosis Type 1 ◽  
Phase Ii Trial ◽  
Neurofibromatosis Type ◽  
Plexiform Neurofibromas

scholarly journals Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas

2014 ◽  
Vol 61 (9) ◽  
pp. 1598-1602 ◽  
Author(s):  
Brigitte C. Widemann ◽  
Dusica Babovic-Vuksanovic ◽  
Eva Dombi ◽  
Pamela L. Wolters ◽  
Stewart Goldman ◽  
...  
Keyword(s):  
Young Adults ◽  
Phase Ii ◽  
Neurofibromatosis Type 1 ◽  
Phase Ii Trial ◽  
Neurofibromatosis Type ◽  
Plexiform Neurofibromas ◽  
Children And Young Adults

Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. TPS10586-TPS10586
Author(s):  
Andrea M Gross ◽  
Andrea Baldwin ◽  
Eva Dombi ◽  
Pamela Wolters ◽  
Patricia Whitcomb ◽  
...  
Keyword(s):  
Phase Ii ◽  
Neurofibromatosis Type 1 ◽  
Phase Ii Study ◽  
Neurofibromatosis Type ◽  
Plexiform Neurofibromas
Sign in / Sign up

Export Citation Format

Share Document